A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy

Karim Fizazi, Albertas Ulys, Lisa Sengeløv, Mette Moe Kempel, Sylvain Ladoire, Antoine Thiery-Vuillemin, Aude Flechon, Roberto Sabbatini, Joaquim Bellmunt, Miguel Angel Climent, Simon Chowdhury, Herlinde Dumez, Michaela Matouskova, Nicolas Penel, Sigita Liutkauskiene, Lech Stachurski, Cora N. Sternberg, Frederique Baton, Nathalie Germann, Gedske Daugaard

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article number201
JournalJournal of Clinical Oncology
Issue number2 Suppl.
Publication statusPublished - 2016
EventGenitourinary Cancers Symposium - San Francisco, United States
Duration: 7 Jan 20169 Jan 2016


ConferenceGenitourinary Cancers Symposium
Country/TerritoryUnited States
CitySan Francisco

Cite this